UNC Eshelman School of Pharmacy

READDI, Not Reactive

For decades, scientists warned of the potential for a global coronavirus outbreak. But when SARS-CoV-2 emerged, no therapeutics, drugs, or vaccines were readily available. The Rapidly Emerging Antiviral Drug Development Initiative (READDI) — founded by researchers at UNC and the Structural Genomics Consortium — is not only finding solutions to the COVID-19 pandemic, but also drugs and therapeutics for future viral outbreaks.
Aaron Anselmophoto by Megan May

Aaron Anselmo

Aaron Anselmo is an assistant professor in the UNC Eshelman School of Pharmacy. He develops new strategies and technologies that alter the microbiome by removing pathogens and increasing beneficial bacteria.
Portrait of Tojan Rahhal.Photo courtesy of Tojan Rahhal

Tojan Rahhal

Tojan Rahhal is a fourth-year PhD student studying pharmaceutical sciences in the UNC Eshelman School of Pharmacy. Under the guidance of Joseph DeSimone, her research focuses on the delivery of therapeutics to the lungs. She is also the chair of UNC’s Women in Science group.